Stay updated with breaking news from Alligator Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months) and overall survival (median 14.3 months) support continued development of mitazalimab in a randomized confir...
Alligator Bioscience AB announced that two clinical abstracts on its lead drug candidate mitazalimab, a best- in-class CD40 agonist, in first line metastatic pancreatic cancer will be presented in a...
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median 12.5 months)
WASHINGTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- As per Vantage Market Research, the Global Immuno-Oncology Clinical Trials Market has been steadily growing over the years due to increasing incidence of cancer, advancements in cancer research, the growing demand for personalized medicine, increased research and development activities in the field of immuno-oncology, as well as advancements in technology and supportive regulatory frameworks. According to Vantage Market Research, the global Immuno-O
The European Medicines Agency has granted orphan drug designation to mitazalimab for use in patients with pancreatic cancer.